» Articles » PMID: 33546463

Neurological Sequelae in Patients with COVID-19: A Histopathological Perspective

Overview
Publisher MDPI
Date 2021 Feb 6
PMID 33546463
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neuroinvasive properties of SARS-CoV-2 have allowed the hypothesis of several pathogenic mechanisms related to acute and chronic neurological sequelae. However, neuropathological correlates have been poorly systematically investigated, being retrieved from reports of single case or limited case series still.

Methods: A PubMed search was carried out to review all publications on autopsy in subjects with "COronaVIrus Disease-19" (COVID-19). Among them, we focused on histological findings of the brain, which were compared with those from the authors' autoptic studies performed in some COVID-19 patients.

Results: Only seven studies reported histological evidence of brain pathology in patients deceased for COVID-19, including three with reverse transcription-quantitative polymerase chain reaction evidence of viral infection. All these studies, in line with our experience, showed vascular-related and infection-related secondary inflammatory tissue damage due to an abnormal immune response. It is still unclear, however, whether these findings are the effect of a direct viral pathology or rather reflect a non-specific consequence of cardiovascular and pulmonary disease on the brain.

Conclusions: Notwithstanding the limited evidence available and the heterogeneity of the studies, we provide a preliminary description of the relationship between SARS-CoV-2 and brain sequelae. Systematic autoptic investigations are needed for accurate detection and adequate management of these patients.

Citing Articles

RESTORE ME: a RCT of oxaloacetate for improving fatigue in patients with myalgic encephalomyelitis/chronic fatigue syndrome.

Cash A, Vernon S, Rond C, Bateman L, Abbaszadeh S, Bell J Front Neurol. 2024; 15:1483876.

PMID: 39664752 PMC: 11632837. DOI: 10.3389/fneur.2024.1483876.


COVID-19 and Mental Health: A "Pandemic Within a Pandemic".

Fisicaro F, Lanza G, Concerto C, Rodolico A, Di Napoli M, Mansueto G Adv Exp Med Biol. 2024; 1458:1-18.

PMID: 39102186 DOI: 10.1007/978-3-031-61943-4_1.


Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.

Naidu A, Wang C, Rao P, Mancini F, Clemens R, Wirakartakusumah A NPJ Sci Food. 2024; 8(1):19.

PMID: 38555403 PMC: 10981760. DOI: 10.1038/s41538-024-00261-2.


Neuroprotective Strategies for Stroke by Natural Products: Advances and Perspectives.

Liu A, Hu J, Yeh T, Wang C, Tang J, Huang X Curr Neuropharmacol. 2023; 21(11):2283-2309.

PMID: 37458258 PMC: 10556387. DOI: 10.2174/1570159X21666230717144752.


SARS‑CoV‑2 and Seizure: An Insight Into the Pathophysiology.

Ahadiat S, Hosseinian Z Anesth Pain Med. 2023; 13(1):e134129.

PMID: 37404265 PMC: 10317025. DOI: 10.5812/aapm-134129.


References
1.
Peleg Y, Kudose S, DAgati V, Siddall E, Ahmad S, Nickolas T . Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney Int Rep. 2020; 5(6):940-945. PMC: 7186120. DOI: 10.1016/j.ekir.2020.04.017. View

2.
Desforges M, Le Coupanec A, Brison E, Meessen-Pinard M, Talbot P . Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans. Adv Exp Med Biol. 2014; 807:75-96. PMC: 7121612. DOI: 10.1007/978-81-322-1777-0_6. View

3.
Krishnan V, Leung L, Caplan L . A neurologist's approach to delirium: diagnosis and management of toxic metabolic encephalopathies. Eur J Intern Med. 2013; 25(2):112-6. DOI: 10.1016/j.ejim.2013.11.010. View

4.
Chua T, Xu Z, King N . Neurological manifestations in COVID-19: a systematic review and meta-analysis. Brain Inj. 2020; 34(12):1549-1568. DOI: 10.1080/02699052.2020.1831606. View

5.
Mendelson M, Nel J, Blumberg L, Madhi S, Dryden M, Stevens W . Long-COVID: An evolving problem with an extensive impact. S Afr Med J. 2021; 111(1):10-12. DOI: 10.7196/SAMJ.2020.v111i11.15433. View